Unity Biotechnology, Inc. Deferred Tax Assets, in Process Research and Development

Unity Biotechnology, Inc. Deferred Tax Assets, in Process Research and Development

Unity Biotechnology, Inc. had Deferred Tax Assets, in Process Research and Development of $6.62 million as of 2022-12-31, per its 10-K filed 2023-03-15.

Discontinued › Notes › Income Taxes › Deferred Tax Assets, Gross

us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2023-03-15

• 2022-12-31: Deferred Tax Assets, in Process Research and Development $6.62M.
• 2021-12-31: Deferred Tax Assets, in Process Research and Development $0.00.